Scientists test if more doses of cancer vaccine can sharpen Body's defenses
NCT ID NCT05806814
Summary
This small, early-stage study is testing whether giving more doses of an existing prostate cancer immunotherapy, called Sipuleucel-T, can create a stronger immune response against the cancer. It will involve about 13 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals are to see if patients can complete the extended treatment schedule and to measure changes in their immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Oklahoma Health Sciences Center, Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.